Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition...
-
All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week...
-
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
-
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
-
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
-
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
-
Lipella Pharmaceuticals to Present Phase 2a Data for LP-10 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
-
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference
-
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
-
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus